Ardelyx (ARDX) Cash from Financing Activities (2014 - 2026)
Ardelyx (ARDX) posted Cash from Financing Activities of $5.4 million for Q1 2026, up 877.02% on a QoQ basis from $557000.0 in Q4 2025, and up 267.21% year-over-year from $1.5 million in Q1 2025.
Ardelyx (ARDX) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Ardelyx's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 267.21% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.5 million (up 6.11% YoY) and the FY2025 annual result came in at $54.5 million, down 48.86% from the prior year.
- Cash from Financing Activities was $5.4 million for Q1 2026 at Ardelyx, up from $557000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $57.9 million in Q3 2023 and bottomed at -$63000.0 in Q1 2022.
- A 5-year average of $22.8 million and a median of $18.8 million in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.18% — and 2023, when it jumped 80923.81%.
- Ardelyx's Cash from Financing Activities stood at $18.8 million in 2022, then jumped by 38.33% to $26.0 million in 2023, then surged by 89.75% to $49.3 million in 2024, then plunged by 98.87% to $557000.0 in 2025, then soared by 877.02% to $5.4 million in 2026.
- Business Quant data shows ARDX's Cash from Financing Activities at $5.4 million in Q1 2026, $557000.0 in Q4 2025, and $2.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Ardelyx | 1.24 Bn | 999.81 Mn | 89.66 Mn | 5.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.44 Mn |
| Mar 31, 2026 | 5.44 Mn |
| Dec 31, 2025 | 557,000.00 |
| Dec 31, 2025 | 557,000.00 |
| Sep 30, 2025 | 2.81 Mn |
| Sep 30, 2025 | 2.81 Mn |
| Jun 30, 2025 | 49.66 Mn |
| Jun 30, 2025 | 49.66 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | 49.31 Mn |
| Dec 31, 2024 | 49.31 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 52.97 Mn |
| Mar 31, 2024 | 52.97 Mn |
| Dec 31, 2023 | 25.99 Mn |
| Dec 31, 2023 | 25.99 Mn |